Erasca, Inc. Shareholder Class Action Lawsuit
June 22, 2026 — The law firm of Federman & Sherwood, a national plaintiffs’ litigation firm representing shareholders and investors in complex securities matters, announces that it has commenced an investigation into potential securities law violations by Erasca, Inc. (“Erasca” or the “Company”) (NASDAQ: ERAS) on behalf of purchasers of the Company’s common stock between January 14, 2025 and April 26, 2026.
Details of the Lawsuit Investigation:
Federman & Sherwood’s investigation focuses on whether Erasca and certain of its officers and directors made materially false or misleading statements, and/or failed to disclose material information to investors regarding the Company’s lead oncology drug candidate, ERAS-0015, its intellectual property position, and its business prospects.
The investigation will examine allegations that Erasca promoted ERAS-0015 as a potentially “best-in-class” therapy and highlighted purportedly superior preclinical results compared to competing drug candidates while failing to disclose material risks associated with those comparisons. The investigation will further assess whether the Company failed to disclose that its conduct could expose it to patent infringement and trade secret misappropriation claims and whether certain statements lacked a reasonable basis when made.
Federman & Sherwood is also investigating whether investors were adequately informed regarding intellectual property disputes involving ERAS-0015. On April 28, 2026, Erasca disclosed that it had received a letter from Revolution Medicines alleging patent infringement and trade secret misappropriation related to ERAS-0015. Following that disclosure, the Company’s stock price declined substantially.
Background:
Erasca, Inc. is a clinical-stage precision oncology company focused on developing therapies designed to target RAS/MAPK pathway-driven cancers. The Company’s common stock is publicly traded, and during the relevant period Erasca issued statements concerning its research programs, clinical development efforts, and future growth prospects. Recent litigation and disclosures have raised questions regarding whether investors were provided complete and accurate information concerning the Company’s lead drug candidate and related intellectual property risks.
What This Means for Investors:
Investors who purchased or otherwise acquired Erasca, Inc. common stock during the relevant period and believe they suffered financial losses may contact Federman & Sherwood for a free and confidential consultation. The firm is evaluating potential legal claims and all available remedies on behalf of affected shareholders.
Contact Information:
Federman & Sherwood
Phone: 405-235-1560 | 1-800-237-1277
Email: info@federmanlaw.com
Website: www.federmanlaw.com